For the past four years, the volume of healthcare services mergers and acquisitions has always slowed in the fourth quarter. While the fourth quarter of 2000 was no exception, the size of the decline was larger than usual and the number of transactions fell below 100, hitting a seven-year low, according to New Canaan, CT-based Irving Levin Associates Inc. In its fourth quarter 2000 Healthcare M&A Report, the firm points out that there were just 90 healthcare services mergers and acquisitions announced, representing a 30% decline from the third quarter and a 43% plunge from the fourth quarter of 1999.
For the past four years, the volume of healthcare services mergers and acquisitions has always slowed in the fourth quarter. While the fourth quarter of 2000 was no exception, the size of the decline was larger than usual and the number of transactions fell below 100, hitting a seven-year low, according to New Canaan, CT-based Irving Levin Associates Inc. In its fourth quarter 2000 Healthcare M&A Report, the firm points out that there were just 90 healthcare services mergers and acquisitions announced, representing a 30% decline from the third quarter and a 43% plunge from the fourth quarter of 1999.
"During a year of bankruptcies, a volatile stock market and new reimbursement methodologies for Medicare, the healthcare services M&A market took a beating," noted Stephen M. Monroe, a partner and managing editor at the firm. However, during the fourth quarter of 2000, the firm began tracking the merger activity in the healthcare technology sectors, which include e-health, medical devices, biotechnology and pharmaceuticals. "With 144 transactions during the quarter, the healthcare technology area is definitely dominating the merger and acquisition market and commanding the attention of investors," Monroe added. The dollar volume of all healthcare-related mergers and acquisitions announced during the fourth quarter was approximately $26 billion, of which almost 85% was in the healthcare technology areas.
The services sector has suffered from the financial distress in the physician medical group, home health and long-term care components of the healthcare market. "Three years ago, there were up to 80 transactions in the physician medical group practice market in one quarter, compared to just eight in the fourth quarter of 2000. Although not as severe, similar declines have occurred in the home health and long-term care segments," said Sanford B. Steever, editor of the report. "With hospital stocks rising throughout 2000, that market has been relatively active, culminating in Triad Hospitals' $2.4 billion offer for Quorum Health Group in the fourth quarter." PR
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.